• About us
• Contact

Advertisement

Organisation › Details

Casebia Therapeutics (GB) (Bayer/CRISPR Therapeutics joint venture)

Casebia Therapeutics is a novel joint venture between Bayer and CRISPR Therapeutics, focused on discovering, developing and commercializing new CRISPR/Cas9-based breakthrough therapeutics to treat blood disorders, blindness, and heart disease. Formed in the first quarter of 2016, the company began operations in the U.S. in August of 2016. Casebia has access to gene-editing technology from CRISPR Therapeutics in specific disease areas, as well as access to protein engineering expertise and relevant disease know-how through Bayer. Casebia is a free-standing entity, equally owned by Bayer and CRISPR Therapeutics, with its own scientific leadership and management team. The company’s Board of Directors has equal composition from Bayer and CRISPR Therapeutics. Casebia’s primary base of research operations is in Cambridge, MA, with a second site in San Francisco, CA. *

 

	Start	2015-12-21 announced jv 50%
	Group	CRISPR Therapeutics (Group)
	Industry	CRISPR gene editing technology
	Industry 2	drug discovery
	Person	Bouchon, Axel (ARCH Venture 202112– Venture Partner + BrainGames before Leaps by Bayer + Moderna Therapeutics)
	Region	London, Greater London
	Country	United Kingdom (GB)
	City	n. a. London
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for CRISPR Therapeutics (Group)

• [1] CRISPR Therapeutics AG. (1/3/24). "Press Release: CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Zug & Boston, MA....
• [2] CRISPR Therapeutics AG. (10/21/19). "Press Release: CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics". Leverkusen, Zug & Cambridge, MA....
• [3] CRISPR Therapeutics AG. (10/2/18). "Press Release: CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference". Zug & Cambridge, MA....
• [4] CRISPR Therapeutics AG. (4/13/17). "Press Release: CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision". Basel, et al.....
• [5] CRISPR Therapeutics AG. (3/28/17). "Press Release: CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing". Basel....
• [6] CRISPR Therapeutics AG. (2/15/17). "Press Release: CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.". Basel...
• [7] Intellia Therapeutics, Inc.. (2/14/17). "Press Release: Joint Statement of Intellia Therapeutics & CRISPR Therapeutics – Position Regarding Human Germline Gene Editing"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.